CompletedPhase 1ACTRN12605000523606
A Phase I Study to Determine the Pharmacokinetics of Nestorone Delivered with the Metered Dose Transdermal System (MDTS) in Postmenopausal Women, to be used in contraception
Sponsor
FemPharm Pty Ltd and/or Acrux DDS Pty Ltd
Enrollment
6 participants
Start Date
Aug 1, 2004
Study Type
Interventional
Conditions
Eligibility
Sex: FemalesMin Age: 18 Yearss
Inclusion Criteria1
- Healthy post-menopausal women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nestorone Metered Dose Transdermal System (MDTS), 6 days.
Nestorone Metered Dose Transdermal System (MDTS), 6 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000523606
Related Trials
Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
NCT059105804 locations
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
NCT064816311 location
Female Reproductive Health in Canadian Armed Forces
NCT075247641 location
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
NCT067277341 location
Long Term Evaluation of Scapular-inserted Contraceptive Implants
NCT072014022 locations